Clinical Effect of Yinhuang Qingfei Capsules in Treatment of Asymptomatic and Mild/Common Severe Acute Respiratory Syndrome Coronavirus 2 Infection:An Analysis of 242 Cases

[Objectives]To investigate the clinical effect of Yinhuang Qingfei capsules in the treatment of asymptomatic and mild/common severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)infection.[Methods]A total of 362 patients with SARS-CoV-2 infection were divided into the treatment group with 242 patients and control group with 120 patients according to their treatment regimen.The patients in the control group were given standard treatment regimen and those in the treatment group were given Yinhuang Qingfei capsules in addition to the treatment in the control group.The two groups were observed in terms of average length of hospital stay,mean time for nucleic acid clearance,TCM syndrome score,and progression to severe/critical illness,and clinical outcome was compared between the two groups.[Results]There was a significant difference in the overall response rate between the treatment group and the control group[97.52%(236/242)vs 95.00%(114/120),P<0.05].Compared with the control group,the treatment group had significantly shorter length of hospital stay and time for nucleic acid clearance(P<0.05).After 7 days of treatment,both groups had a significant change in TCM syndrome score,and there was a significant difference in TCM syndrome score between the two groups(P<0.05);after 15 days of treatment,both groups had a TCM syndrome score of 0.Progression to severe/critical illness was not observed in either group.[Conclusions]Compared with the standard treatment regimen alone,standard treatment regimen combined with Yinhuang Qingfei capsules can effectively shorten the length of hospital stay and time for nucleic acid clearance and improve TCM symptoms in patients with asymptomatic and mild/common SARS-CoV-2 infection.

PillCam Colon 2 capsule in patients unable or unwilling to undergo colonoscopy

AIM: To assess the feasibility, accuracy and acceptability of PillCam Colon 2 in detection of significant lesions in colorectal cancer risk patients, unable or unwilling to perform colonoscopy. METHODS: This is a prospective, single center study using the second generation of PillCam Colon capsule. In all patients the readers were instructed to review the entire colon capsule endoscopy(CCE) examination using Rapid 7 software and additionally to note significant extra-colonic findings. Colonic significant findings were described according to European Society of Gastrointestinal Endoscopy guidelines. CCE procedure completion rate, level of bowel preparation and rate of adverse events were assessed. RESULTS: A total of 70 patients at risk of colorectal cancer were enrolled in the study. In three patients the procedure failed because the capsule was not functioning when entered the colon. PillCam Colon 2 showed positive findings in 23(34%, 95%CI: 21.6%-44.1%) of the remaining 67 patients. Six patients were diagnosedwith tumors: 4 with colon cancers, 1 with gastric cancer and 1 with a small bowel cancer. The capsule findings were confirmed after surgery in all these patients. The capsule excretion rate in twelve hours was 77% with 54 patients having a complete examination. The rectum was not explored during CCE procedure, in 16 patients(23%, 95%CI: 13.7%-34.1%). Every patient accepted CCE as an alternative exploration tool and 65/70(93%) agreed to have another future control by CCE. No complications were reported during or after CCE examination. CONCLUSION: PillCam Colon 2 capsule was effective in detecting significant lesions and might be considered an adequate alternative diagnostic tool in patients unable or unwilling to undergo colonoscopy.

Comparison of the diagnostic yield and outcomes between standard 8 h capsule endoscopy and the new 12 h capsule endoscopy for investigating small bowel pathology

AIM: To evaluate the completion rate and diagnostic yield of the Pill Cam SB2-ex in comparison to the Pill Cam SB2.METHODS:Two hundred cases using the 8-h Pill Cam SB2 were retrospectively compared to 200 cases using the 12 h Pill Cam SB2-ex at a tertiary academic center.Endoscopically placed capsules were excluded from the study.Demographic information,indications for capsule endoscopy,capsule type,study length,completion of exam,clinically significant findings,timestamp of most distant finding,and significant findings beyond 8 h were recorded.RESULTS:The 8 and 12 h capsule groups were well matched respectively for both age(70.90±14.19vs 71.93±13.80,P=0.46)and gender(45.5%vs48%male,P=0.69).The most common indications for the procedure in both groups were anemia and obscure gastrointestinal bleeding.Pill Cam SB2-ex had a significantly higher completion rate than Pill Cam SB2(88%vs 79.5%,P=0.03).Overall,the diagnostic yield was greater for the 8 h capsule(48.5%for SB2vs 35%for SB2-ex,P=0.01).In 4/70(5.7%)of abnormal SB2-ex exams the clinically significant findingwas noted in the small bowel beyond the 8 h mark.CONCLUSION:In our study,we found the Pill Cam SB2-ex to have a significantly increased completion rate,though without any improvement in diagnostic yield compared to the Pill Cam SB2.

Effect of rhBMP-2 sustained-release nanocapsules on the ectopic osteogenesis process in Sprague-Dawley rats

Objective:To explore the effect of sustained-release recombinant human bone morphogenetic protein-2(rhBMP-2) on ectopic osteogenesis in the muscle pouches of rats through preparing rhBMP-2 sustained-release capsules by wrapping morphogenesis protein bones-2(BMP-2)using chitosan nanoparticles,and compositing collagen materials.Methods:Twenty four SpragueDawley rats were randomly divided into four groups with six rats in each group,that is Group A(control group),Group B(only treated with collagen),Group C(rhBMP-2+collagen treated group) and Group D(rhBMP-2/cs+collagen treated group).The composite materials for each group were implanted in the bilateral peroneal muscle pouches in rats.The peroneal muscles were only separated without implanting any materials in control group.Rats were sacrificed 2 weeks and 4 weeks post treatment and samples were cut off for general observation,Micro CT scans and histological observation.Results:General observation showed no new bone formation in Groups A and B mice,while new bones were formed in Groups C and D mice.Two weeks after treatment Micro CT scans showed that The bone volume fraction(BVF),trabecular thickness(Tb. Th),bone mineral density(BMD) in Group C mice were all higher than that in Group D(P<0.05). At the fourth week,the BVK,Tb.Th and BMD were significantly higher than that at the second week(P<0.01).Conclusions:The slow-release effect of rhBMP-2/cs sustained-release capsules can significantly promote ectopic osteogenesis.Its bone formation effect is better than that of rhBMP-2 burst-release group.

Hollow MOF capsule encapsulated amino-functionalized ionic liquid for excellent CO_(2) catalytic conversion

The engineering of highly efficient and stable heterogeneous catalysts for catalytic conversion of CO_(2) to high value-added products is highly desirable but presents a great challenge. Herein, we reported the synthesis of a series of multifunctional IL@H-Zn/Co-ZIF composite catalysts with a unique porous hollow capsule structure and encapsulated amino-functionalized ionic liquids(ILs). The unique hollow capsule structure of IL@H-Zn/Co-ZIF provides sufficient space for loading active ILs([C_(2)NH_(2) Mim+][Brà]) and fast mass transfer of substrate molecules during catalysis. Furthermore, the microporous Zn-ZIF shell can effectively avoid the leaching of active ILs. Benefiting from the unique hollow structure, the resultant IL@H-Zn/Co-ZIF demonstrated excellent catalytic performance(>95% yield), and good recyclability(still remained about 90% activities after 5 cycles) when applied in the CO_(2) cycloaddition reaction under solvent and co-catalyst free conditions.

No significant difference in clinically relevant findings between Pillcam~? SB3 and Pillcam~? SB2 capsules in a United States veteran population

BACKGROUND Capsule endoscopy(CE) allows for a non-invasive small bowel evaluation for a wide range of gastrointestinal(GI) symptoms and diseases. Capsule technology has been rapidly advancing over recent years, often improving image frequency and quality. The Pillcam~? SB3(SB3) capsule is one such technology that offers an adaptive frame rate advantage over the previous versions of the capsule the Pillcam~? SB2(SB2). Some have proposed that this improvement in capsule technology may lead to increased diagnostic yields; however, real world clinical data is currently lacking.AIM To evaluate the clinically relevant findings of SB3 and SB2 capsules in a population of United States veterans.METHODS A retrospective analysis of 260 consecutive CE studies was performed including130 SB3 and 130 SB2 capsule studies. Recorded variables included: age, gender,type of capsule, body mass index, exam completion, inpatient status, opioid use,diabetes, quality of preparation, gastric transit time, small bowel transit time,indication, finding, and if the exam resulted in a change in clinical management.The primary outcome measured was the detection of clinically relevant findings between SB3 and SB2 capsules.RESULTS Mean age of the study population was 67.1 ± 10.4 years and 94.2% of patients were male. Of these 28.1% were on opioid users. The most common indications for capsule procedure were occult GI bleeding(74.6%) and overt GI bleeding(14.6%). Rates of incomplete exam were similar between SB3 and SB2 groups(16.9% vs 9.2%, P = 0.066). The overall rate of clinically relevant finding was48.9% in our study. No significant difference was observed in SB3 vs SB2 capsules for clinically relevant findings(46.2% vs 51.5%, P = 0.385) or change in clinical management(40.8% vs 50.0%, P = 0.135).CONCLUSION Our study found no significant difference in clinically relevant findings between SB3 and SB2 capsules.

汉防己甲素对人眼Tenon囊成纤维细胞中bax、bcl-2、TGF-β2 mRNA表达的影响

目的观察汉防己甲素(Tet)对体外培养的人眼Tenon囊成纤维细胞(tenon's capsule fibroblasts,TCFS)中bax、bcl-2、转化生长因子-β2(TGF-β2)mRNA表达的影响,探讨其可能的作用机制。方法将体外培养的第3代TCFS分别置于浓度为10-5mol/LTet的培养液和1640培养液中培养48 h,采用实时荧光定量PCR检测细胞中bax、bcl-2和TGF-β2 mRNA的表达变化。结果同对照组比较,Tet实验组中bax mRNA的表达量明显升高,bcl-2、TGF-β2 mRNA的表达量显著下降,差异均有统计学意义(P<0.05)。结论一定浓度的汉防己甲素可以通过降低bcl-2、TGF-β2 mRNA的表达量,同时提高bax mRNA的表达量来抑制TCFS的增殖,并可诱导其凋亡,可能成为一种潜在的抗青光眼滤过瘢痕药物。

玉泉胶囊对2型糖尿病合并非酒精性脂肪性肝病患者糖脂代谢功能的影响

目的探讨玉泉胶囊对2型糖尿病(T2DM)合并非酒精性脂肪性肝病(NAFLD)患者糖脂代谢功能的影响。方法选取医院2023年2月至12月收治的T2DM合并NAFLD患者100例,按随机数字表法分为观察组和对照组,各50例,两组各剔除1例,最终各纳入49例。两组患者均予二甲双胍,并结合饮食控制,观察组患者加用玉泉胶囊,两组患者均连续治疗6个月。结果观察组总有效率为87.76%,显著高于对照组的67.35%(P<0.05);治疗后,观察组患者的空腹血糖、糖化血红蛋白、餐后2 h血糖、低密度脂蛋白胆固醇、胰岛素抵抗指数均显著低于对照组,高密度脂蛋白胆固醇显著高于对照组(P<0.05);观察组患者的血清γ-谷氨酰基转移酶、天门冬氨酸氨基转移酶、丙氨酸氨基转移酶、体质量指数、非酒精性脂肪性肝纤维化评分(NAFLDFS)、超声肝脏回声衰减系数和肝肾回声比值均显著低于对照组(P<0.05)。观察组和对照组不良反应发生率相当(12.24%比8.16%,P>0.05)。结论玉泉胶囊治疗T2DM合并NAFLD的临床疗效较好,可有效改善患者的糖脂代谢功能,减轻胰岛素抵抗,延缓NAFLD进展,且安全性良好。

归芪胶囊对家兔心肌缺血—再灌注损伤中MDACa^(2+)NO影响的实验研究

目的 :探讨归芪胶囊对家兔心肌缺血—再灌注损伤的保护作用。方法 :以冠状动脉前降支结扎法进行动物造模 ,以家兔血清中MDA、Ca2 + 及NO为指标进行实验观察。结果 :归芪胶囊对心肌缺血—再灌注损伤家兔血清中MDA与Ca2 + 的降低及NO的升高有统计学意义 (P <0 .0 1)。结论 :归芪胶囊通过对MDA、Ca2 + 和NO含量的影响 ,对再灌注心肌损伤有保护作用。

Effect of Danzhijiangtang capsule on monocyte chemoattractant protein-1 mRNA expression in newly diagnosed diabetes subclinical vascular lesions

AIM:To investigate the effect of Danzhijiangtang capsule(DJC) on monocyte chemoattractant protein-1(MCP-1) mRNA expression in newly diagnosed type 2 diabetes mellitus(T2DM) subclinical vascular lesions.METHODS:Sixty-two patients with newly diagnosed T2DM subclinical vascular lesions were randomly divided into a control group and treatment group of 31 cases each.Oral antidiabetic therapy with routine western medicine was conducted in both groups,and the treatment group was additionally treated with DJCs.The treatment course for both groups was 12 wk.Before and after treatment,the total efficiency and traditional Chinese medicine(TCM) syndrome score were calculated.The fasting plasma glucose(FPG),2-h plasma glucose(2hPG),fasting insulin(FINS),insulin resistance index(IRI),hemoglobin(Hb)A1c,blood lipids,and hemorheology indices were determined.In addition,the levels of vascular endothelial growth factors including thrombomodulin(TM),von Willebrand factor(vWF),P-selectin and MCP-1 mRNA were determined.RESULTS:After 12 wk of treatment,the TCM syndrome score was significantly decreased compared to before treatment in both groups.After treatment,FPG,2hPG,HbA1c,FINS,IRI,total cholesterol,triglycerides,low-density lipoprotein,high-density lipoprotein,whole blood low shear specific viscosity,plasma specific viscosity,TM,vWF,P-selectin and MCP-1 mRNA were significantly improved compared to before treatment in both groups.After treatment,the total efficiency and TCM syndrome score in the treatment group were better than in the control group.FINS,IRI,whole blood high shear specific viscosity,plasma specific viscosity,TM,vWF,P-selectin and MCP-1 mRNA level in the treatment group were significantly reduced after treatment compared with control group.CONCLUSION:DJCs are efficacious in supplementing qi,nourishing yin and invigorating blood circulation,and upregulate MCP-1 mRNA expression in patients with T2DM subclinical vascular lesions.

骨化三醇胶丸联合胰激肽原酶对2型糖尿病微血管并发症患者外周血Hcy、RBP4、SAA水平的影响

目的观察骨化三醇胶丸联合胰激肽原酶对2型糖尿病微血管并发症患者外周血同型半胱氨酸(Hcy)、视黄醇结合蛋白4(RBP4)、淀粉样蛋白A(SAA)水平的影响。方法前瞻性选取2020年1月至2022年12月秦皇岛市第二医院收治的104例2型糖尿病微血管并发症患者为对象,采用随机数字表法分为常规组(n=52)和骨化三醇组(n=52)。两组均接受利拉鲁肽治疗,常规组加用胰激肽原酶治疗,骨化三醇组在常规组基础上联合骨化三醇胶丸治疗。比较两组糖代谢(空腹血糖、餐后2 h血糖)、Hcy、RBP4、SAA、正五聚蛋白3(PTX3)及骨代谢指标[25-羟基维生素D(25(OH)D)、骨碱性磷酸酶(BAP)、骨保护素(OPG)、Ⅰ型前胶原氨基端延长肽(P1NP)、Ⅰ型前胶原氨基端延长肽(β-CTX)、碱性磷酸酶(ALP)]的水平差异,统计两组不良反应发生情况。结果治疗后,两组的空腹血糖、餐后2 h血糖均较治疗前降低,差异均有统计学意义(P<0.05);但骨化三醇组和常规组组间比较,差异均无统计学意义(P>0.05)。治疗后,骨化三醇组和常规组的Hcy、RBP4、SAA、PTX3水平均较治疗前降低,差异均有统计学意义(P<0.05),且骨化三醇组Hcy、RBP4、SAA、PTX3水平分别为(10.23±2.06)μmol/L、(32.85±5.15)mg/L、(23.01±3.86)μg/mL、(18.11±3.23)ng/mL,均低于常规组[(11.90±2.14)μmol/L、(37.25±6.58)mg/L、(29.23±3.74)μg/mL、(22.03±4.01)ng/mL],差异均有统计学意义(P<0.05)。治疗后,骨化三醇组25(OH)D、BAP、OPG水平均较治疗前升高,P1NP、β-CTX、ALP水平均较治疗前降低,差异均有统计学意义(P<0.05),常规组骨代谢指标治疗前后比较,差异均无统计学意义(P>0.05);骨化三醇组25(OH)D、BAP、OPG水平分别为(21.89±2.23)ng/mL、(38.98±4.74)μg/L、(312.52±34.41)ng/L,均高于常规组[(18.96±2.41)ng/mL、(31.52±4.06)μg/L、(279.96±31.04)ng/L],骨化三醇组P1NP、β-CTX、ALP水平分别为(41.66±4.26)ng/mL、(0.38±0.11)ng/mL、(5.08±0.89)U/L,均低于常规组[(45.89±5.01)ng/mL、(0.46±0.14)ng/mL、(6.61±1.21)U/L],差异均有统计学意义(P<0.05)。骨化三醇组高钙血症、头痛或头晕、胃肠道反应、皮疹、泌尿道感染等不良反应发生率为11.54%,与常规组的7.69%比较,差异无统计学意义(P>0.05)。结论骨化三醇胶丸联合胰激肽原酶治疗2型糖尿病微血管并发症可改善患者骨代谢指标,降低患者血清Hcy、RBP4、SAA、PTX3水平,且不增加不良反应。

Effect of compound preparation Tongqiao Jiannao capsules on neural cell apoptosis and Bcl-2 and Bax protein levels in a rat model of brain ischemia/reperfusion injury

BACKGROUND：Pharmacological studies have demonstrated that compound preparation Tongqiao Jiannao capsules composed of Zexie, Baizhu, Honghua, Danshen, and Shexiang can supplement qi, activate blood circulation, relieve blood stasis, induce resuscitation for alleviating pain, relieve pain, and dilate blood vessels. OBJECTIVE： To observe the effects of Tongqiao Jiannao capsules on the levels of the anti-apoptotic protein Bcl-2 and the proapoptotic protein Bax, and verify the mechanism of action. DESIGN, TIME AND SETTING： Randomized, controlled animal experiment, performed in the Laboratory of Biochemistry and Molecular Biology, Shanxi Medical University between June 2001 and December 2002. MATERIALS： The right middle cerebral arteries of 24 healthy adult Sprague Dawley rats were occluded by the suture method. The primary Chinese herbal medicinal ingredients of Tongqiao Jiannao capsules are Zexie, Baizhu, Honghua, Danshen, and Shexiang, which were purchased from Shanxi Provincial Medicinal Material Company, China, and prepared into condensed granules in the Room for Chinese Herbal Medicine Preparation, Second Hospital, Shanxi Medical University. Bcl-2 and Bax immunohistochemical staining kits, a 3,3-diaminobenzidine（DAB） kit, and an in situ apoptosis detection kit were purchased from Wuhan Boster Bioengineering Co., Ltd., China. METHODS： Twenty-four rats were randomly and evenly divided into three groups： （1） sham-operated rats in which sutures were inserted and immediately pulled out; （2） Tongqiao Jiannao capsule-treated rats that were intragastrically administered 6.5 g/kg/d Tongqiao Jiannao capsule preparation for seven successive days prior to middle cerebral artery occlusion （MCAO）; and （3） MCAO rats without any other treatments. MAIN OUTCOME MEASURES： The levels of neural cell apoptosis and Bcl-2 and Bax proteins at 24 hours post-surgery. RESULTS： In the MCAO group, the numbers of apoptotic cells and Bax-positive cells were significantly increased, while the numbers of Bcl-2-positive cells were slightly decreased compared with the sham-operated group. Bcl-2- and Bax-positive cells and apoptotic cells were primarily distributed in the ischemic penumbra. In the Tongqiao Jiannao capsule-treated group, neuronal apoptosis was inhibited, and the number of Bcl-2-positive cells was significantly increased （P 〈 0.01）, while the number of Bax-positive cells was significantly decreased （P 〈 0.01）, compared with the MCAO group. CONCLUSION： Tongqiao Jiannao capsules elevated Bcl-2 expression, lowered Bax expression, and inhibited cellular apoptosis during the process of cerebral ischemia/reperfusion injury.

First Pillcam Colon 2 capsule images of Whipple's disease:Case report and review of the literature

Whipple's disease is a rare chronic systemic infection determined by the Gram-positive bacillus Tropheryma whipplei.The infection usually mainly involves the small bowel,but sometimes other organs are affected as well.Since the current standard clinical and biological tests are nonspecific,diagnosis is very difficult and relies on histopathology.Here we present the case of a 52-yearold man with chronic diarrhea and weight loss whose symptoms had been evolving for 2 years and whose diagnosis came unexpectedly after capsule examination.Diagnosis was confirmed by the histopathologic examination of endoscopic biopsy samples,and treatment with co-trimoxazole resulted in remission of symptoms.We present the first images of Whipple's disease obtained with the Pillcam Colon 2 video capsule system.

Preparation and phase change performance of Na_2HPO_4·12H_2O@poly(lactic acid) capsules for thermal energy storage

Micro-encapsulated phase-change materials(micro PCMs) with Na_2 HPO_4·12 H_2 O encapsulated in poly(lactic acid)(PLA) shell were prepared by a solvent evaporation–precipitation method that involves the use of a coaxial needle. The effects of PLA concentration, stirring speed, injection rate of core and shell solutions, and polyvinyl alcohol(PVA) concentration on phase change properties were investigated. The thermal properties of microP CMs were characterized by differential scanning calorimetry(DSC). The capsules prepared under the optimal conditions are about 2 mm in diameter and show a latent heat of up to 122.2 J·g^(-1).

晚期胃癌患者参一胶囊联合化疗治疗前后血清Bcl⁃2、Bax、Fas与预后的相关性

目的研究晚期胃癌患者血清B细胞淋巴瘤⁃2基因(Bcl⁃2)、Bcl⁃2相关X蛋白(Bax)、自杀相关因子(Fas)与参一胶囊联合化疗治疗预后的相关性。方法选择2019年1月至2023年4月在安徽省颍上县人民医院进行参一胶囊联合化疗的72例晚期胃癌患者患者并进行1年随访,随访期间存活的患者作为预后良好组(n=48)、死亡的患者作为预后不良组(n=24)。比较两组患者治疗前各项临床资料及血清Bcl⁃2、Bax、Fas水平的差异,采用logistic回归分析预后的影响因素,采用受试者工作特征(ROC)曲线分析血清Bcl⁃2、Bax、Fas对预后的预测效能。结果预后不良组晚期患者参一胶囊联合化疗治疗前的血清癌胚抗原、糖类抗原199、Bcl⁃2水平高于预后良好组,差异有统计学意义(t=4.749、5.032、6.033,P<0.05);血清Bax、Fas水平低于预后良好组,差异有统计学意义(t=5.067、7.018,P<0.05)。治疗前血清Bcl⁃2水平升高是晚期胃癌患者参一胶囊联合化疗治疗预后不良的危险因素,Bax、Fas水平升高是晚期胃癌患者参一胶囊联合化疗治疗预后不良的保护因素(P<0.05)。血清Bcl⁃2、Bax、Fas及血清Bcl⁃2+Bax+Fas均对晚期胃癌患者参一胶囊联合化疗治疗的预后具有预测价值,血清Bcl⁃2+Bax+Fas预测预后的灵敏度和特异度均为87.5%。结论血清Bcl⁃2增加、Bax和Fas降低与晚期胃癌患者参一胶囊联合化疗治疗预后不良有关,治疗前血清Bcl⁃2+Bax+Fas对预后具有预测价值。

Efficacy of Juanbi capsule on ameliorating knee osteoarthritis:a network pharmacology and experimental verification-based study

Background:The purpose of the study was to investigate the active ingredients and potential biochemical mechanisms of Juanbi capsule in knee osteoarthritis based on network pharmacology,molecular docking and animal experiments.Methods:Chemical components for each drug in the Juanbi capsule were obtained from Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform,while the target proteins for knee osteoarthritis were retrieved from the Drugbank,GeneCards,and OMIM databases.The study compared information on knee osteoarthritis and the targets of drugs to identify common elements.The data was imported into the STRING platform to generate a protein-protein interaction network diagram.Subsequently,a“component-target”network diagram was created using the screened drug components and target information with Cytoscape software.Common targets were imported into Metascape for GO function and KEGG pathway enrichment analysis.AutoDockTools was utilized to predict the molecular docking of the primary chemical components and core targets.Ultimately,the key targets were validated through animal experiments.Results:Juanbi capsule ameliorated Knee osteoarthritis mainly by affecting tumor necrosis factor,interleukin1β,MMP9,PTGS2,VEGFA,TP53,and other cytokines through quercetin,kaempferol,andβ-sitosterol.The drug also influenced the AGE-RAGE,interleukin-17,tumor necrosis factor,Relaxin,and NF-κB signaling pathways.The network pharmacology analysis results were further validated in animal experiments.The results indicated that Juanbi capsule could decrease the levels of tumor necrosis factor-αand interleukin-1βin the serum and synovial fluid of knee osteoarthritis rats and also down-regulate the expression levels of MMP9 and PTGS2 proteins in the articular cartilage.Conclusion:Juanbi capsule may improve the knee bone microstructure and reduce the expression of inflammatory factors of knee osteoarthritis via multiple targets and multiple signaling pathways.

丁苯酞软胶囊联合瑞舒伐他汀治疗急性脑梗死患者的临床观察及对血清HIF-1α、Lp-PLA、Sestrin2水平的影响

目的探究丁苯酞软胶囊联合瑞舒伐他汀治疗急性脑梗死患者的疗效及对血清缺氧诱导因子-1α(HIF-1α)、脂蛋白相关磷脂酶A2(Lp-PLA)、应激诱导蛋白2(Sestrin2)水平的影响。方法前瞻性选取2021年1月至2022年12月在秦皇岛市第一医院治疗的急性脑梗死患者101例作为研究对象,按照信封法将患者分为对照组(n=50)和研究组(n=51)。对照组行常规治疗并瑞舒伐他汀治疗,研究组在对照组基础上联合丁苯酞软胶囊治疗。统计分析两组患者治疗前及治疗14 d后的美国国立卫生研究院脑卒中量表(NIHSS)评分、FuglMeyer评测法(FMA)评分、改良Rankin量表(mRS)评分、血流动力学指标(血浆黏度、全血高切黏度、低切黏度、红细胞压积、红细胞变形指数)、血清HIF-1α、Lp-PLA、Sestrin2水平并比较临床疗效的组间差异。结果治疗14 d后,两组患者的NIHSS评分和mRS评分均较治疗前降低,FMA较治疗前升高,且研究组患者的NIHSS评分和mRS评分分别为(4.03±0.38)、(3.01±0.45)分,均低于对照组,FMA为(80.64±9.16)分,高于对照组,差异均有统计学意义(P<0.05)。治疗14 d后,两组患者的血浆黏度、全血高切黏度、低切黏度、红细胞压积均较治疗前降低,红细胞变形指数均较治疗前升高,且研究组的血浆黏度、全血高切黏度、低切黏度、红细胞压积分别为(1.56±0.33)mPa·s、(4.78±0.31)mPa·s、(9.81±0.64)mPa·s、(0.37±0.05)%,均低于对照组,红细胞变形指数为0.78±0.11,高于对照组,差异均有统计学意义(P<0.05)。治疗14 d后,两组患者的血清HIF-1α、Lp-PLA、Sestrin2水平均降低,且研究组患者血清HIF-1α、Lp-PLA、Sestrin2水平分别为(690.56±65.12)ng/mL、(13.65±2.13)μg/L、(11.33±1.45)ng/mL,均显著低于对照组,差异均有统计学意义(P<0.05)。两组近期疗效比较,差异有统计学意义(P<0.05);研究组总有效率为90.20%,高于对照组(64.00%),差异有统计学意义(P<0.05)。结论采用丁苯酞软胶囊联合瑞舒伐他汀治疗急性脑梗死患者可显著提高患者临床治疗效果,提高肢体活动能力,缓解神经功能损伤,降低血清HIF-1α、Lp-PLA、Sestrin2水平,具有较高的临床应用潜力。

PillCamColon2 after incomplete colonoscopy-A prospective multicenter study

AIM To evaluate the ability of PillCamColon2 to visualize colonic segments missed by incomplete optical colonoscopy(OC) and to assess the diagnostic yield.METHODS This prospective multicentre study included 81 patients from nine centres who underwent second-generation colon capsule endoscopy(CCE) following incomplete OC performed by an experienced gastroenterologist(> 1000 colonoscopies). Patients with stenosis were excluded. According to patient preferences, CCE was performed the following day(protocol A) after staying on clear liquids and 0.75 L Moviprep in the morning or within 30 d after new split-dose Moviprep(protocol B). Boosts consisted of 0.75 L and 0.25 L Moviprep, and phospho-soda was given as a rescue if the capsule was not excreted after seven hours.RESULTS Seventy-four patients were analysed(51% of them in group A; 49% in group B). Bowel cleansing was adequate in 67% of cases, and CCE could visualize colonic segments missed by incomplete colonoscopy in 90% of patients under protocol A and 97% of patients under protocol B(P = 0.35, n.s.). Significant polyps including adenocarcinoma were detected in 24% of cases. Detection rates for all polyps and significant polyps per patient were similar in both protocols. Polyps were found predominantly in the right colon(86%) in segments that were not reached by OC. Extracolonic findings-such as reflux esophagitis, suspected Barrett esophagus, upper GI-bleeding, gastric polyps, gastric erosions and angiectasia-were detected in eight patients. Pill Cam Colon2 capsule was retained in the ileum of one patient(1.4%) without symptoms and removed during an uneventful resection for unknown Crohn's disease that was diagnosed as the cause of anemia, which was the indication for colonoscopy. CCE was well tolerated. One patient suffered from selflimiting vomiting after consuming the phospho-soda.CONCLUSION Second-generation CCE using a low-volume preparation is useful after incomplete OC, and it allows for the detection of additional relevant findings, but cleansing efficiency could be improved.

Effect of Modulen vs budesonide on clinical response and mucosal healing in Crohn’s patients

BACKGROUND Mucosal healing has become an important goal of Crohn’s disease(CD)treat-ments.Modulen,enriched with transforming growth factor-beta 2,and budeso-nide are commonly accepted treatments for mild-moderate CD.However,their effects on the small bowel(SB)mucosa remain underexplored.AIM To prospectively assess clinical and mucosal responses to Modulen vs budesonide in adults with CD,using SB capsule endoscopy.METHODS Thirty patients were divided into two groups:Modulen+home-based diet(21 patients)and budesonide(9 patients)for an eight-week intervention followed by four weeks of follow-up.Clinical,laboratory,and endoscopic responses were evaluated.The mucosal changes were assessed through SB capsule endoscopy.RESULTS Results indicated significant clinical improvement in the Modulen group with reduced CD activity index(P=0.041)and improved inflammatory bowel disease questionnaire score(P=0.016).Moreover,Modulen was associated with a signifi-cant SB mucosal improvement,evidenced by a decrease in Lewis score(P=0.027).No significant changes were observed in calprotectin or other laboratory parame-ters.Conversely,budesonide exhibited more modest clinical effects,but it improved calprotectin,hemoglobin,and C-reactive protein levels(P=0.051,P=0.014,and P=0.038,respectively).The capsule endoscopy did not reveal a significant mucosal response in the budesonide group.CONCLUSION Both interventions have a role in CD treatment.Yet,their effects differ and may complement each other:Modulen yields clinical and mucosal improvements,while budesonide primarily leads mainly to laboratory improvements.

温心胶囊对大鼠实验性缺血心肌细胞凋亡及Bcl-2、Fas蛋白表达的影响

目的 :探讨临床有效中药复方温心胶囊防治冠心病心肌缺血的分子作用机制。方法 :采用盐酸异丙肾上腺素连续多点皮下注射制备大鼠心肌缺血模型。运用透射电镜技术及TUNEL法 ,观察温心胶囊对缺血损伤大鼠心肌细胞凋亡的影响 ,并运用免疫组化的方法观察其对细胞凋亡相关基因Bcl 2、Fas蛋白表达的影响。结果 :异丙肾上腺素所致心肌缺血损伤可明显诱导大鼠心肌细胞发生凋亡 ,显著引发Fas基因蛋白表达增强 ,并轻度引发Bcl 2基因蛋白表达增强 ,温心胶囊可显著下调Fas基因的蛋白表达 ,上调Bcl 2基因的蛋白表达 ,明显抑制和阻断心肌细胞发生凋亡。结论 :通过调节缺血心肌Bcl 2、Fas基因的蛋白表达从而抑制和阻断细胞凋亡的发生 ,可能是中药复方温心胶囊防治冠心病心肌缺血损伤的分子作用机制之一。